Cohen Klingenstein LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 130,223 shares of the company’s stock after selling 241 shares during the quarter. Eli Lilly and Company accounts for approximately 3.4% of Cohen Klingenstein LLC’s portfolio, making the stock its 7th largest holding. Cohen Klingenstein LLC’s holdings in Eli Lilly and Company were worth $101,513,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. ST Germain D J Co. Inc. increased its position in shares of Eli Lilly and Company by 3.4% in the first quarter. ST Germain D J Co. Inc. now owns 1,667 shares of the company’s stock valued at $1,377,000 after buying an additional 55 shares in the last quarter. HBW Advisory Services LLC raised its stake in shares of Eli Lilly and Company by 1.4% during the 1st quarter. HBW Advisory Services LLC now owns 1,648 shares of the company’s stock worth $1,361,000 after buying an additional 23 shares during the last quarter. Finally, Triangle Securities Wealth Management raised its stake in shares of Eli Lilly and Company by 30.3% during the 1st quarter. Triangle Securities Wealth Management now owns 4,814 shares of the company’s stock worth $3,976,000 after buying an additional 1,120 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company Price Performance
Eli Lilly and Company stock opened at $825.92 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a 50 day moving average price of $733.71 and a 200 day moving average price of $766.37. The company has a market cap of $781.70 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 1.06 and a beta of 0.47.
Wall Street Analyst Weigh In
Several analysts have issued reports on LLY shares. Guggenheim reduced their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. HSBC raised Eli Lilly and Company from a “reduce” rating to a “hold” rating and raised their price target for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. Cantor Fitzgerald reduced their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Finally, Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $939.61.
View Our Latest Stock Report on Eli Lilly and Company
Insider Buying and Selling at Eli Lilly and Company
In other news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- Top Biotech Stocks: Exploring Innovation Opportunities
- Datavault AI: The New AI Contender Backed by Big Funding
- A Deeper Look at Bid-Ask Spreads
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- Canada Bond Market Holiday: How to Invest and Trade
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.